The global generic injectable market size was exhibited at USD 90 billion in 2022 and it is expected to hit around USD 326.39 billion by 2032, expanding at a CAGR of 13.8% during the forecast period from 2023 to 2032.
The generic injectable drug is the compound having therapeutic characteristics with increased efficiency, potent. Which focus to kill the disease or the chronic infection. The generic drug basically is the chemical substance with increased developments and continuous research have increased the availability of the generic drugs in the market with fast approval of the drug. There are two categorisation involves generic drug and branded drug. Generic drug is basically same with the branded drug with same active pharmaceutical ingredient, with equal safety, quality, strength, efficiency, output of the drug, route of administration is same of both generic and branded drugs.
Therefore, increased focus on producing and manufacturing the generic drug with increased efficiency and decreased adverse drug reactions of the generic drugs. Increased chronic diseases among the population with increased medications enhanced the market of generic injectable drugs. Changing lifestyle of the people with increased diseases strives the market growth. Increased various new launch of the generic drugs as that of branded drugs with expiry of patents which reduced the new launch of the drug. Which helps to boost the market of generic injectable.
Impact of covid-19 viral disease, wide spread of virus across the regions with increase patient hospitalisation rate with increased demand for the drugs which fuels the market growth of generic drugs with cost effective benefit from the generic drugs.
Report Scope of the Generic Injectable Market
|Market Size in 2023||
USD 101.97 Billion
|Market Size by 2032||
USD 326.39 Billion
|Growth Rate from 2023 to 2032||
CAGR of 13.8%
2023 to 2032
Product Type, Molecular Type, Application, Administration, Distribution Channel, and Geography
|Companies Mentioned||DR. Reddys Laboratries Ltd, Baxter International, Mylan N.A, Teva Pharmaceuticals, Astra Zeneca Plc, Sanofi S.A, Fresenius Kabi, Pfizer Inc, Cipla Ltd, Merck & Co. Inc, Novartis AG, Sun Pharmaceutical Industries Ltd, Aurobindo Pharma Limited, Samsung Biologics Co Ltd, Biocon, Lupin,Ltd, Astrazeneca, GlaxoSmithKline Plc, Hikma Pharmaceuticals, Cosette Pharmaceutical, Inc, Johnson & Johnson Services, Inc, Sanofi SA, Amgen Inc., Bristol- Myers Squibb Company, Piramal Pharma Solutions, Merck KGaA|
The advanced developed drugs with increased efficacy of the drugs with increased research and development for producing the new generic drugs with fast approval of the new drug for increasing chronic diseases across the regions with increased adoption of the new lifestyle and habitual has increased the number of diseases, different dietary intake which is the major factor of increasing the disease. Increasing population with increasing infectious disease which led to short of generic injectable drugs which increased production of the generic drugs enhanced the market to grow at a larger extend.
Generic injectable drugs are less expensive than the branded drugs with increased cost of the drugs. Generic drug is highly affordable for the customers with very low cost of the drugs. Which led to increased demands from the health care sector for the generic injectable with increased efficacy and therapeutic index. Expansion of the generic injectable with various developments in routes of administration with increased research and developments in generic drugs drives the market of generic injectable with increased demand. Brand injectable comes with the expiry of the patent therefore reduced the number of introductions of the new drugs. Which led to increase research, production and manufacturing of the generic injectables fuels the market growth.
Research and development steps are less than branded drugs with fast approval and production of the generic injectable with increased demand from the health care sector expanded the market growth. The key market players involved in introducing the new generic drugs with increased investment for research and developed helps to boost the market growth at a larger extent during the forecast period. Increased government interest in developing the generic injectables due to decreased launch of the generic drugs and low cost of the generic with increased investment have rise the market to grow high.
Key Market Drivers
Rising prevalence of chronic infectious diseases
Increased population in the regions with increased infectious diseases among the people which led to increased number of patients for hospitalization with increased demand for the generic injectable drugs. Branded drugs come with patent expiry with decreased launch of the new generic injectable drug therefore expanded the demand for the generic injectables with similar efficacy, quality, strength, potent, safety. Which boosts the generic injectable market to a greater extend.
Cost effectivity of the generic injectables
Key Market Challenges
Key Market Opportunities
Product Type Insight
Monoclonal antibodies to hold the highest market share with increased revenue during the forecast period of generic injectables.
Molecule Type Insight
Increased research and development in large molecules for developing the generic injectables with increased opportunity and increased share in the market.
Which helps to increase the market of generic injectables. However, the small molecule segment is poised to grow at a higher CAGR during the forecast period 2023 to 2032.
Increased growth of the diabetes disease with increased life style and dietary supplements with high rate of patients among the population due to the previous family or increased obesity. Which led to increase of the diabetes with increased demand for the generic injectables. Oncology is also rising from the year 2022 with increased chemotherapies and generic injectables with high demand for the medication from the health care centre. However, the diabetes segment is growing at the strongest CAGR from 2023 to 2032.
Distribution Channel Insight
Segmentation of generic injectables based on distribution channel involves Hospital pharmacy, retail pharmacy, drug stores and online pharmacy. Due to increased chronic infectious diseases with enlargement of the hospitals with their own hospital pharmacy increase growth of the hospital across the regions. Hospital pharmacy to hold the largest market.
Generic Injectable Market Share, By Region, 2022 (%)
|Regions||Revenue Share in 2022 (%)|
Segmentation of generic injectables based on geography sector North America to be the leading region with highest market growth of the generic injectables with increased development of the generic injectables with increased research and development from the key market players for introducing the generic injectables with increased demand from the health care center due to shortage of the injectable with increased chronic infectious diseases among the population with increased hospitalization rate of the patients.
Asia pacific region also helps to boost the market growth with increased demand from the health care centre for generic injectables with increased chronic diseases increasing due to rising population. Other regions such as Europe, Latin America, Middle East and Africa contributes to increase the market of generic injectables to a larger extend.
Key Market Players
Segments Covered in the Report
By Product Type
By Molecular Type
By Distribution Channel
PROCEED TO BUY :
ASK FOR SAMPLE
No cookie-cutter, only authentic analysis – take the 1st step to become an Precedence Research client